Tibin K. Titus, Mercer University College of Pharmacy
Postmenopausal osteoporosis occurs due to estrogen deficiency resulting in an increase of mature osteoclasts, which will increase bone resorption into the blood.  Simultaneously, there is a decrease in calcium absorption and increase in calcium excretion through the gut.  Romosozumab is a new monoclonal antibody that is in development for treatment of osteoporosis in postmenopausal women at increased risk of fractures.  In a previous trial, romosozumab reduced the risk of fracture compared to placebo; however, it has not been compared with an active comparator.  This study was conducted with an active comparator, alendronate, to compare the two drugs for fracture prevention in postmenopausal women with osteoporosis.